NEA Management Company, LLC reported 26 holdings worth US$1.59B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
NEA Management Company, LLC reported 26 holdings worth US$1.59B as of Jun 30, 2026. Largest: Trevi Therapeutics, Inc., Mbx Biosciences, Inc. and Monte Rosa Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 26
- Value as reported
- US$1.59B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Trevi Therapeutics, Inc. | 13.2M | US$247M | 15.5% |
| Mbx Biosciences, Inc. | 3.61M | US$200M | 12.6% |
| Monte Rosa Therapeutics, Inc. | 7.69M | US$186M | 11.7% |
| Celcuity Inc. | 1.71M | US$179M | 11.3% |
| Spyglass Pharma, Inc. | 7.39M | US$165M | 10.4% |
| Savara, Inc. | 24.5M | US$151M | 9.5% |
| Zenas Biopharma, Inc. | 4.02M | US$102M | 6.4% |
| Coursera, Inc. | 12.9M | US$72.6M | 4.6% |
| Aurinia Pharmaceuticals Inc | 3.97M | US$67.4M | 4.2% |
| Oric Pharmaceuticals, Inc. | 4.12M | US$44.6M | 2.8% |
| Phathom Pharmaceuticals, Inc. | 1.96M | US$21.3M | 1.3% |
| Korro Bio, Inc. | 1.3M | US$17.1M | 1.1% |
| Champions Oncology, Inc. | 1.71M | US$10.6M | 0.66% |
| Nkarta, Inc. | 3.57M | US$10.1M | 0.64% |
| Cvrx, Inc. | 1.95M | US$10M | 0.63% |
| Black Diamond Therapeutics, Inc. | 4.45M | US$8.23M | 0.52% |
| Karyopharm Therapeutics Inc. | 577K | US$5.64M | 0.35% |
| Inventiva Sa | 1.46M | US$5.53M | 0.35% |
| Leonabio, Inc. | 464K | US$4.27M | 0.27% |
| Marker Therapeutics, Inc. | 1.63M | US$2.39M | 0.15% |
| Onkure Therapeutics, Inc. | 479K | US$2.18M | 0.14% |
| Imagenebio, Inc. | 50,005 | US$295K | 0.02% |
| Gossamer Bio, Inc. | 1M | US$165K | 0.01% |